Levetiracetam for pediatric migraine prophylaxis: A narrative review

IF 1.4 4区医学 Q4 CLINICAL NEUROLOGY Brain & Development Pub Date : 2024-11-17 DOI:10.1016/j.braindev.2024.104304

Maryam Shahrokhi , Amir Mohammad Davari Fard Pur , Negar Shafaei-Bajestani , Habibeh Mashayekhi-sardoo

{"title":"Levetiracetam for pediatric migraine prophylaxis: A narrative review","authors":"Maryam Shahrokhi , Amir Mohammad Davari Fard Pur , Negar Shafaei-Bajestani , Habibeh Mashayekhi-sardoo","doi":"10.1016/j.braindev.2024.104304","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Migraine, a common primary headache disorder, affects children and adolescents under 18, often bilateral and lasting 2–72 hours, affecting 7.7% of them.</div></div><div><h3>Objective</h3><div>Recent studies on migraine prevention and treatment in children and adolescents have explored the potential benefits of levetiracetam, considering its side effects and potential effects on migraines. Hence, we aimed to review the studies that have examined the possible mechanism and beneficial effects of levetiracetam in children's and adolescents' migraine.</div></div><div><h3>Methods</h3><div>A comprehensive search of English and non-English trials evaluating levetiracetam's effectiveness in pediatric migraine treatment using relevant keywords was conducted in scientific databases including PubMed, Web of Science, and the Cochrane Controlled Trials Register in Feb 2024. The studies included non-randomized controlled trials, uncontrolled trials, and retrospectively reviewed medical charts plus randomized controlled trials.</div></div><div><h3>Results</h3><div>Seven studies were included in this review. They revealed that levetiracetam can promisingly complete the resolution of migraines, and decrease the duration, severity, number of migraine episodes, and frequency of migraine in children. In addition, levetiracetam diminished the Pediatric Migraine Disability Assessment Scale score in them.</div></div><div><h3>Conclusion</h3><div>Seven studies suggest levetiracetam, at doses ranging from 20 to 60 mg/kg/day (250–3000 mg/day), can significantly reduce migraine frequency and duration, but larger controlled trials are needed.</div></div>","PeriodicalId":56137,"journal":{"name":"Brain & Development","volume":"47 1","pages":"Article 104304"},"PeriodicalIF":1.4000,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain & Development","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0387760424001578","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Migraine, a common primary headache disorder, affects children and adolescents under 18, often bilateral and lasting 2–72 hours, affecting 7.7% of them.

Objective

Recent studies on migraine prevention and treatment in children and adolescents have explored the potential benefits of levetiracetam, considering its side effects and potential effects on migraines. Hence, we aimed to review the studies that have examined the possible mechanism and beneficial effects of levetiracetam in children's and adolescents' migraine.

Methods

A comprehensive search of English and non-English trials evaluating levetiracetam's effectiveness in pediatric migraine treatment using relevant keywords was conducted in scientific databases including PubMed, Web of Science, and the Cochrane Controlled Trials Register in Feb 2024. The studies included non-randomized controlled trials, uncontrolled trials, and retrospectively reviewed medical charts plus randomized controlled trials.

Results

Seven studies were included in this review. They revealed that levetiracetam can promisingly complete the resolution of migraines, and decrease the duration, severity, number of migraine episodes, and frequency of migraine in children. In addition, levetiracetam diminished the Pediatric Migraine Disability Assessment Scale score in them.

Conclusion

Seven studies suggest levetiracetam, at doses ranging from 20 to 60 mg/kg/day (250–3000 mg/day), can significantly reduce migraine frequency and duration, but larger controlled trials are needed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用于小儿偏头痛预防的左乙拉西坦：叙述性综述。

背景：偏头痛是一种常见的原发性头痛疾病：偏头痛是一种常见的原发性头痛疾病，多发于18岁以下的儿童和青少年，常为双侧性，持续2-72小时，发病率为7.7%：最近关于儿童和青少年偏头痛预防和治疗的研究探讨了左乙拉西坦的潜在益处，同时考虑到其副作用和对偏头痛的潜在影响。因此，我们旨在回顾研究左乙拉西坦对儿童和青少年偏头痛的可能机制和有益作用：方法：2024 年 2 月，我们使用相关关键词在科学数据库（包括 PubMed、Web of Science 和 Cochrane Controlled Trials Register）中对评估左乙拉西坦在儿童偏头痛治疗中有效性的英文和非英文试验进行了全面检索。研究包括非随机对照试验、无对照试验、回顾性病历以及随机对照试验：本综述共纳入七项研究。研究显示，左乙拉西坦能有效缓解偏头痛，并能缩短偏头痛的持续时间、减轻偏头痛的严重程度、减少偏头痛的发作次数和频率。此外，左乙拉西坦还能降低儿童偏头痛残疾评估量表的评分：七项研究表明，左乙拉西坦的剂量为20至60毫克/千克/天（250至3000毫克/天），可显著减少偏头痛的频率和持续时间，但仍需进行更大规模的对照试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Brain & Development 医学-临床神经学

CiteScore

3.60

自引率

0.00%

发文量

153

审稿时长

50 days

期刊介绍： Brain and Development (ISSN 0387-7604) is the Official Journal of the Japanese Society of Child Neurology, and is aimed to promote clinical child neurology and developmental neuroscience. The journal is devoted to publishing Review Articles, Full Length Original Papers, Case Reports and Letters to the Editor in the field of Child Neurology and related sciences. Proceedings of meetings, and professional announcements will be published at the Editor''s discretion. Letters concerning articles published in Brain and Development and other relevant issues are also welcome.